Lupin receives USFDA's approval for Ethacrynic Acid Tablets

09 Sep 2019 Evaluate

Lupin has received approval for its Ethacrynic Acid Tablets USP, 25 mg, from the United States Food and Drug Administration (USFDA).

The company’s Ethacrynic Acid Tablets USP, 25 mg, is the generic version of Edecrin Tablets, 25 mg, of Bausch Health Americas, Inc. It is indicated for treatment of edema when an agent with greater diuretic potential than those commonly employed is required. Ethacrynic Acid Tablets USP (RLD: Edecrin Tablets) had annual sales of approximately $24 million in the US (IQVIA MAT June 2019).

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.

Lupin Share Price

2312.70 -22.25 (-0.95%)
30-Mar-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1757.35
Dr. Reddys Lab 1254.65
Cipla 1223.05
Zydus Lifesciences 871.20
Lupin 2312.70
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×